Novo Nordisk

Comments have been turned off on this post. You can still react or repost it.

Did you miss the Novo Nordisk symposium at ESC 2026? Explore the key takeaways from “Clinical translation of GLP-1 RAs for adiposity-driven HFpEF: From guidelines to practice”: • The link between HFpEF, adiposity, and cardiovascular risk • How GLP-1 RAs may benefit patients with HFpEF • Practical considerations for GLP-1 RA treatment • Emerging developments in cardiometabolic care Swipe through the summary - and watch the full symposium to hear the experts discuss translating the latest evidence into clinical practice. Learn more: https://lnkd.in/g9uh7MJ6